AbbVie Inc. Discloses Material Impairment
Ticker: ABBV · Form: 8-K · Filed: 2025-01-10T00:00:00.000Z
Sentiment: neutral
Topics: impairment, disclosure
Related Tickers: ABBV
TL;DR
AbbVie flagged a big impairment charge, could be bad news.
AI Summary
On January 9, 2025, AbbVie Inc. filed an 8-K report indicating a material impairment. The filing does not specify the exact amount of the impairment or the assets affected, but it is a significant event requiring disclosure.
Why It Matters
Material impairments can signal a significant decline in the value of a company's assets, potentially impacting future earnings and investor confidence.
Risk Assessment
Risk Level: medium — Material impairments suggest a significant negative event impacting asset values, which warrants investor attention.
Key Players & Entities
- AbbVie Inc. (company) — Registrant
- January 9, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-35565 (filing_id) — SEC File Number
FAQ
What specific assets are subject to the material impairment at AbbVie Inc.?
The filing does not specify the exact assets affected by the material impairment.
What is the estimated financial impact of the material impairment on AbbVie Inc.?
The filing does not disclose the specific dollar amount of the material impairment.
When did the event triggering the material impairment occur for AbbVie Inc.?
The earliest event reported in relation to the material impairment occurred on January 9, 2025.
Is this material impairment related to a specific business segment or product line of AbbVie Inc.?
The filing does not provide details on whether the impairment is tied to a specific segment or product.
What is the reason behind the material impairment at AbbVie Inc.?
The filing does not state the specific reasons for the material impairment.
From the Filing
0001551152-25-000006.txt : 20250110 0001551152-25-000006.hdr.sgml : 20250110 20250110083146 ACCESSION NUMBER: 0001551152-25-000006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250109 ITEM INFORMATION: Material Impairments FILED AS OF DATE: 20250110 DATE AS OF CHANGE: 20250110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 25520585 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20250109.htm 8-K abbv-20250109 0001551152 false 0001551152 2025-01-09 2025-01-09 0001551152 exch:XNYS us-gaap:CommonStockMember 2025-01-09 2025-01-09 0001551152 exch:XCHI us-gaap:CommonStockMember 2025-01-09 2025-01-09 0001551152 exch:XNYS abbv:Sec0.750SeniorNotesDue2027Member 2025-01-09 2025-01-09 0001551152 exch:XNYS abbv:Sec2.125SeniorNotesdue2028Member 2025-01-09 2025-01-09 0001551152 exch:XNYS abbv:Sec2625SeniorNotesDue2028Member 2025-01-09 2025-01-09 0001551152 exch:XNYS abbv:Sec2125SeniorNotesDue2029Member 2025-01-09 2025-01-09 0001551152 exch:XNYS abbv:Sec1.250SeniorNotesdue2031Member 2025-01-09 2025-01-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  _____________________________________________________ FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): January 9, 2025   ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware   001-35565   32-0375147 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)  _____________________________________________________ 1 North Waukegan Road North Chicago ,  Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐                       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 0.750% Senior Notes due 2027 ABBV27 New York Stock Exchange 2.125% Senior Notes due 2028 ABBV28 New York Stock Exchange 2.625% Senior Notes due 2028 ABBV28B New York Stock Exchange 2.125% Senior Notes due 2029 AB